|
CHMP2B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.63602464908763E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.32005517627931E-13 |
| Normal-vs-Stage2 |
1.72909999995863E-06 |
| Normal-vs-Stage3 |
1.02689967640401E-10 |
| Normal-vs-Stage4 |
2.76000333698789E-11 |
| Stage1-vs-Stage2 |
4.875800E-01 |
| Stage1-vs-Stage3 |
9.595600E-01 |
| Stage1-vs-Stage4 |
2.184400E-01 |
| Stage2-vs-Stage3 |
5.242200E-01 |
| Stage2-vs-Stage4 |
1.450430E-01 |
| Stage3-vs-Stage4 |
2.815200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.35127497869325E-14 |
| Normal-vs-AfricanAmerican |
1.61507999999477E-05 |
| Normal-vs-Asian |
5.80390002724585E-09 |
| Caucasian-vs-AfricanAmerican |
8.345000E-01 |
| Caucasian-vs-Asian |
6.997600E-01 |
| AfricanAmerican-vs-Asian |
6.620200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.12083692222132E-13 |
| Normal-vs-Female |
2.00173211339916E-12 |
| Male-vs-Female |
1.780790E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.28830279777503E-11 |
| Normal-vs-Age(41-60Yrs) |
2.26441088102547E-12 |
| Normal-vs-Age(61-80Yrs) |
9.4829033514543E-11 |
| Normal-vs-Age(81-100Yrs) |
9.825500E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.533200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.671400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.564000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.852600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.007600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.440000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.714800E-01 |
| Classical-VS-Follicular |
4.044400E-01 |
| Classical-VS-Other |
2.656800E-01 |
| Classical-VS-Normal |
2.02005079330547E-12 |
| Tall-VS-Follicular |
4.043400E-01 |
| Tall-VS-Other |
1.818440E-01 |
| Tall-VS-Normal |
1.6148699999996E-05 |
| Follicular-VS-Other |
5.112000E-01 |
| Follicular-VS-Normal |
2.47630005389965E-09 |
| Other-VS-Normal |
2.824800E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.82027742773516E-13 |
| Normal-vs-N1 |
1.30980004620085E-10 |
| N0-vs-N1 |
3.178400E-01 |
|
|
